Tag Archives: Ivantis

Ivantis Fires Back: It Petitions for Invalidation of the Glaukos iStent® Patent

Last month, it was reported that Glaukos filed a lawsuit against Ivantis, alleging that the Ivantis Hydrus Microstent device infringes on patents held by Glaukos covering its iStent® devices. See “Glaukos Sues Ivantis over patents on iStent® Devices”.

Ivantis has now launched a response: In a filing on May 23, 2018, Ivantis has petitioned the USPTO to invalidate one of the two patents asserted by Glaukos in its lawsuit. Continue reading

Glaukos Sues Ivantis over patents on iStent® Devices

April 17, 2018: Glaukos Corporation of San Clemente, CA, has filed a patent infringement lawsuit against Ivantis, Inc. of Irvine, CA. The lawsuit was filed April 14, 2018.

The patents involved are:
U.S. Patent No. 6,626,858 (Lynch et al.), “Shunt Device and Method For Treating Glaucoma”
U.S. Patent No. 9,827,143 (Lynch et al.), “Shunt Device and Method For Treating Ocular Disorders”

In its Complaint, Glaukos alleges that the Ivantis Hydrus Microstent device infringes on patents held by Glaukos covering its iStent® devices.
Continue reading

Ivantis, Inc.: Application published: “Method and Devices for Increasing Aqueous Humor Outflow”

December 21, 2017: The USPTO today published a patent application filed by Ivantis, Inc. of Irvine, CA: U.S. Application Publication No. 2017/0360609, “Method and Devices for Increasing Aqueous Humor Outflow”.

According to the published abstract:

An ocular implant having an inlet portion and a Schlemm’s canal portion distal to the inlet portion, the inlet portion being disposed at a proximal end of the implant and sized and configured to be placed within an anterior chamber of a human eye, the Schlemm’s canal portion being arranged and configured to be disposed within Schlemm’s canal of the eye when the inlet portion is disposed in the anterior chamber.

Published Claim 1 recites:

1. An ocular implant comprising:
a longitudinally extending body having an inlet portion and a Schlemm’s canal portion distal to the inlet portion, the inlet portion being configured to extend into and be in fluid communication with an anterior chamber of a human eye and the Schlemm’s canal portion being configured to be inserted into Schlemm’s canal adjacent to collector channels of the eye;
a plurality of alternating spines and frames positioned longitudinally along at least a portion of the Schlemm’s canal portion wherein the plurality of alternating spines and frames define a central channel extending therethrough, with the central channel being in fluid communication with the inlet portion;
each of the spines having edges partially defining an opening across from the central channel and in fluid communication with the central channel; and
each of the frames including first and second struts, the first and second struts each having an edge contiguous with an edge of an adjacent spine, the edges defining the opening in fluid communication with the central channel;
wherein the ocular implant is configured to provide at least a 121% increase in average outflow facility of aqueous humor from the anterior chamber through the collector channels of the eye.

The published application can be viewed at the USPTO website at http://pdfaiw.uspto.gov/.aiw?Docid=20170360609.

Note: A published application is not an issued patent. The USPTO automatically publishes most applications 18 months after filing, and the publication is simply a copy of the as-filed application, without examination.

Ivantis: Application published: “Single Operator Device for Delivering an Ocular Implant”

October 12, 2017: The USPTO today published a patent application filed by Ivantis, Inc. of Irvine, CA: U.S. Application Publication No. 2017/0290705, “Single Operator Device for Delivering an Ocular Implant”.

According to the published abstract:

An ocular implant delivery system is provided with a number of features. In some embodiments, the delivery system comprises a rotation mechanism configured to rotate and orient a cannula of the system, and an advancement mechanism configured to advance and retract an ocular implant through the delivery system and into an eye of a patient. In some embodiments, the cannula is sized and configured to be inserted into Schlemm’s canal of the eye. The ocular implant is configured to maintain its orientation within the delivery system as the cannula is rotated. In some embodiments, the ocular implant automatically disengages the delivery system when it is advanced beyond a distal tip of the delivery system. Methods of implanting an ocular implant are also provided.

Claim 15 recites:

15. A method of implanting an ocular implant into Schlemm’s canal of an eye, comprising:
rotating an orientation mechanism of a delivery device to align a cannula with Schlemm’s canal;
advancing the cannula through a corneal incision and into the eye;
piercing Schlemm’s canal with the cannula;
controlling an advancement mechanism of the delivery system with a first hand to advance the ocular implant from the delivery system into Schlemm’s canal;
holding a gonioscope with a second hand during the controlling step to visualize implantation of the ocular implant into Schlemm’s canal; and
automatically disengaging the ocular implant from the delivery system when the ocular implant is advanced beyond a distal tip of the cannula.

The published application can be viewed at the USPTO website at http://pdfaiw.uspto.gov/.aiw?Docid=20170290705.

Note: A published application is not an issued patent. The USPTO automatically publishes most applications 18 months after filing, and the publication is simply a copy of the as-filed application, without examination.

Ivantis obtains patent: “Single operator device for delivering an ocular implant”

July 4, 2017: Ivantis, Inc. of Irvine, CA, obtained U.S. Patent No. 9,693,899, “Single operator device for delivering an ocular implant”.

According to the abstract of the patent:

An ocular implant delivery system is provided with a number of features. In some embodiments, the delivery system comprises a rotation mechanism configured to rotate and orient a cannula of the system, and an advancement mechanism configured to advance and retract an ocular implant through the delivery system and into an eye of a patient. In some embodiments, the cannula is sized and configured to be inserted into Schlemm’s canal of the eye. The ocular implant is configured to maintain its orientation within the delivery system as the cannula is rotated. In some embodiments, the ocular implant automatically disengages the delivery system when it is advanced beyond a distal tip of the delivery system. Methods of implanting an ocular implant are also provided.

The patent may be viewed at the USPTO website at http://pdfpiw.uspto.gov/.piw?Docid=09693899.

Ivantis obtains patent: “Methods and apparatus for treating glaucoma”

July 4, 2017: Ivantis, Inc. of Irvine, CA, obtained U.S. Patent No. 9,693,902, “Methods and apparatus for treating glaucoma”.

According to the abstract of the patent:

An ocular implant for treating glaucoma is provided, which may include any number of features. More particularly, the present invention relates to implants that facilitate the transfer of fluid from within one area of the eye to another area of the eye. One feature of the implant is that it includes a proximal inlet portion and a distal inlet portion adapted to be inserted into the anterior chamber of the eye, and an intermediate portion adapted to be inserted into Schlemm’s canal. Another feature of the implant is that it can be biased to assume a predetermined shape to aid in placement within the eye.

The patent may be viewed at the USPTO website at http://pdfpiw.uspto.gov/.piw?Docid=09693902.

Ivantis Announces FDA Clearance to Initiate Clinical Trial of the Hydrus(TM) Microstent for Minimally Invasive Glaucoma Surgery (MIGS) in Patients with Advanced Glaucoma

Ivantis Inc. of Irvine, CA, developer of the novel Hydrus™ Microstent device, designed to lower eye pressure for glaucoma patients, announced on April 25, 2017 that the US Food and Drug Administration (FDA) has granted the company clearance to initiate a second investigational device exemption (IDE) clinical trial of the Hydrus Microstent. According to details of the announcement:

This trial will involve patients with advanced glaucoma, undergoing stand-alone glaucoma surgery without combined cataract surgery.

The clearance comes on the heels of a $25 million Series C financing announced last quarter by Ivantis, in support of the anticipated 2018 FDA approval of the Hydrus Microstent in patients with mild to moderate glaucoma and undergoing cataract surgery. Continue reading

Ivantis obtains patent: “Ocular implants with asymmetric flexibility”

April 4, 2017: Ivantis, Inc. of Irvine, CA, obtained U.S. Patent No. 9,610,196, “Ocular implants with asymmetric flexibility”.

According to the abstract of the patent:

An ocular implant having an inlet portion and a Schlemm’s canal portion distal to the inlet portion, the inlet portion being disposed at a proximal end of the implant and sized and configured to be placed within an anterior chamber of a human eye, the Schlemm’s canal portion being arranged and configured to be disposed within Schlemm’s canal of the eye when the inlet portion is disposed in the anterior chamber.

The patent may be viewed at the USPTO website at http://pdfpiw.uspto.gov/.piw?Docid=09610196.

Ivantis obtains patent: “Ocular implant system and method”

February 28, 2017: Ivantis, Inc. of Irvine, CA, obtained U.S. Patent No. 9,579,234, “Ocular implant system and method”.

According to the abstract of the patent:

A method of treating glaucoma in a human eye by inserting a distal exit port of a cannula at least partially into Schlemm’s canal of the eye; delivering a dye through the cannula into Schlemm’s canal; identifying obstructions within Schlemm’s canal; and delivering an ocular implant through the cannula into Schlemm’s canal.

The patent may be viewed at the USPTO website at http://pdfpiw.uspto.gov/.piw?PageNum=0&docid=09579234.

Ivantis Finds $25M For Microstent Surgery Devices

Irvine-based medical device developer Ivantis, which is developing microstents for minimally invasive glaucoma surgery, has raised $25M in a Series C funding, the company announced today. The funding was led by RA Capital Management, a new investor, and also included Merieux Developpement, along with existing investors. The company said the funding gives it runway until 2020, and support commercialization of its product in the United States. The company says it is anticipating approval by the FDA in 2018 of its device. Dave Van Meter is President and CEO of Ivantis. Microstents are used in glaucoma surgery to relieve intraocular pressure in a patient’s eye–the root cause of glaucoma. Untreated, that pressure on a patient’s optic nerve can cause permanent loss of vision.